biomerica
reports
fiscal
quarter
financial
results
irvine
globe
newswire
biomerica
nasdaq
bmra
global
provider
advanced
medical
products
today
reported
financial
results
fiscal
quarter
ended
august
net
sales
three
months
ended
august
million
compared
net
sales
million
period
net
loss
million
three
months
ended
august
compared
net
loss
million
period
previous
year
research
development
r
expense
million
three
months
ended
august
compared
million
period
previous
year
increase
increase
r
investment
expense
primarily
due
development
several
tests
including
new
antigen
test
company
working
complete
validation
testing
product
successful
enable
launch
new
antigen
test
several
weeks
pending
international
regulatory
clearances
company
also
expects
r
investment
decrease
prepares
move
remaining
test
products
development
manufacturing
sales
selling
general
administrative
expenses
three
months
ended
august
million
compared
million
period
previous
year
increase
due
increase
reserves
aged
receivables
increase
legal
fees
lesser
extent
higher
salaries
due
several
new
employees
hired
help
manage
company
projected
growth
cash
cash
equivalents
million
current
assets
million
august
leveraging
technology
expertise
able
develop
tests
detect
antibodies
quickly
wait
fda
issue
emergency
use
authorization
eua
antibody
elisa
serology
blood
test
completing
work
covid
test
line
part
efforts
planning
launch
antigen
test
preparing
launch
elisa
product
outside
us
ce
mark
filing
point
care
applications
certain
products
believe
introduction
antigen
test
enable
us
offer
complete
line
point
care
products
testing
addition
also
worked
diligently
differentiate
products
competition
focusing
simple
blood
collection
device
enables
blood
samples
collected
virtually
anywhere
corporation
university
organization
trained
professional
device
used
conjunction
elisa
serology
test
said
zackary
irani
ceo
biomerica
international
demand
disposable
antibody
test
decreased
quarter
believe
decrease
due
part
lower
daily
infection
rate
summer
months
international
markets
operate
well
increase
customer
focus
virus
testing
pcr
antigen
tests
importantly
enter
fall
winter
months
daily
rate
new
infections
rising
number
persons
infected
continues
increase
seeing
increases
demand
antigen
antibody
tests
addition
encouraged
see
revenues
related
products
negatively
affected
pandemic
starting
recover
concluded
irani
biomerica
nasdaq
biomerica
global
biomedical
technology
company
develops
patents
manufactures
markets
advanced
diagnostic
therapeutic
products
used
home
physicians
offices
hospital
clinical
laboratories
detection
treatment
medical
conditions
diseases
company
products
designed
enhance
health
people
reducing
total
healthcare
costs
biomerica
primarily
focus
gastrointestinal
inflammatory
diseases
company
multiple
diagnostic
therapeutic
products
development
biomerica
ibs
product
designed
allow
physicians
identify
patient
specific
foods
eggs
broccoli
wheat
potatoes
corn
etc
removed
diet
may
alleviate
improve
individual
ibs
symptoms
including
limited
constipation
diarrhea
bloating
pain
indigestion
patented
therapy
designed
allow
patient
specific
guided
dietary
regimen
improve
ibs
outcomes
product
developed
allow
physicians
perform
test
using
finger
stick
blood
sample
clinical
lab
version
product
expected
first
company
seek
regulatory
approval
billable
cpt
code
used
clinical
labs
physicians
offices
already
available
diagnostic
products
since
product
therapy
drug
drug
type
side
effects
estimated
million
people
america
currently
suffer
ibs
making
leading
cause
patient
doctor
visits
private
securities
litigation
reform
act
provides
safe
harbor
statements
certain
information
included
press
release
well
information
included
oral
statements
written
statements
made
made
biomerica
contains
statements
statements
relating
efficacy
company
tests
fda
clearance
eua
clearance
rapidity
testing
results
uniqueness
product
pricing
company
test
kits
increase
demand
demand
international
orders
availability
company
test
kits
patent
protection
test
technology
information
involves
important
risks
uncertainties
could
significantly
affect
anticipated
results
future
including
without
limitation
results
studies
testing
efficacy
company
tests
regulatory
approvals
necessary
prior
commercialization
company
tests
availability
company
test
kits
capacity
resource
constraints
suppliers
completion
validation
testing
dependence
third
party
manufacturers
dependence
international
shipping
carriers
governmental
import
export
regulations
demand
various
tests
competition
similar
products
competitors
significantly
financial
resources
available
governmental
virus
control
regulations
make
difficult
impossible
company
maintain
current
operations
regulations
company
ability
obtain
patent
protection
aspects
rapid
test
technology
accordingly
results
may
differ
materially
expressed
statements
made
behalf
biomerica
additionally
potential
risks
uncertainties
include
among
others
fluctuations
company
operating
results
due
business
model
expansion
plans
downturns
international
national
economies
company
ability
raise
additional
capital
competitive
environment
company
competing
company
dependence
strategic
relationships
company
obligation
update
statements
date
release
corporate
contact
company
spokesperson
